Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009
JA Gallego, J Bonetti, J Zhang, JM Kane… - Schizophrenia research, 2012 - Elsevier
OBJECTIVE: To assess the prevalence and correlates of antipsychotic polypharmacy (APP)
across decades and regions. METHODS: Electronic PubMed/Google Scholar search for …
across decades and regions. METHODS: Electronic PubMed/Google Scholar search for …
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
BackgroundDespite increased cardiometabolic risk in individuals with mental illness taking
antipsychotic medication, metabolic screening practices are often incomplete or …
antipsychotic medication, metabolic screening practices are often incomplete or …
[BOK][B] The Maudsley prescribing guidelines
D Taylor, C Paton - 2009 - taylorfrancis.com
One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …
The impact of serious mental illness on health and healthcare
MJ Viron, TA Stern - Psychosomatics, 2010 - Elsevier
Background Patients with serious mental illness (SMI; eg, psychotic disorders and major
mood disorders) die earlier, have more medical illnesses, and receive worse medical care …
mood disorders) die earlier, have more medical illnesses, and receive worse medical care …
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
OBJECTIVE: To determine whether the coprescribing of two or more antipsychotics, a
relatively frequent practice with little data to support its safety and efficacy, is associated with …
relatively frequent practice with little data to support its safety and efficacy, is associated with …
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Background The treatment of schizophrenia with multiple antipsychotic drugs is common,
but the benefits and risks are not known. Methods In a randomized, double-blind study, we …
but the benefits and risks are not known. Methods In a randomized, double-blind study, we …
Safety and tolerability of antipsychotic polypharmacy
Introduction: Antipsychotic polypharmacy (APP), the concomitant use of≥ 2 antipsychotics,
is common in clinical practice. Prior reviews have focused on the efficacy of APP, but no …
is common in clinical practice. Prior reviews have focused on the efficacy of APP, but no …
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
People with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and
hypertension than the general population. This results in an increased incidence of …
hypertension than the general population. This results in an increased incidence of …
Diagnostic overshadowing: a potential barrier to physical health care for mental health service users
M Nash - Mental Health Practice, 2013 - journals.rcni.com
Diagnostic overshadowing occurs when symptoms of physical illness are attributed to the
service user's mental illness. This increases the risks of treatment delay and the …
service user's mental illness. This increases the risks of treatment delay and the …
A UK audit of screening for the metabolic side effects of antipsychotics in community patients
TRE Barnes, C Paton, MR Cavanagh… - Schizophrenia …, 2007 - academic.oup.com
Reviews of the association between psychotic disorder, the metabolic syndrome, diabetes,
and antipsychotic drugs conclude that there is a need for active, routine physical health …
and antipsychotic drugs conclude that there is a need for active, routine physical health …